{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T19:13:57Z","timestamp":1696360437787},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T00:00:00Z","timestamp":1353628800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s12325-012-0067-z","type":"journal-article","created":{"date-parts":[[2012,11,24]],"date-time":"2012-11-24T14:14:29Z","timestamp":1353766469000},"page":"993-1004","source":"Crossref","is-referenced-by-count":4,"title":["Linagliptin\/Metformin Fixed-Dose Combination Treatment: A Dual Attack to Type 2 Diabetes Pathophysiology"],"prefix":"10.1007","volume":"29","author":[{"given":"Chrysi","family":"Koliaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Doupis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,23]]},"reference":[{"key":"67_CR1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.287.3.360","volume":"287","author":"S.E. Inzucchi","year":"2002","unstructured":"Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360\u2013372.","journal-title":"JAMA."},{"key":"67_CR2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clinthera.2006.03.005","volume":"28","author":"K.M. Fox","year":"2006","unstructured":"Fox KM, Gerber Pharmd RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002. Clin Ther. 2006;28:388\u2013395.","journal-title":"Clin Ther"},{"key":"67_CR3","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s12325-008-0076-1","volume":"25","author":"J. Doupis","year":"2008","unstructured":"Doupis J, Veves A. DPP inhibitors: a new approach in diabetes treatment. Adv Ther. 2008;25:627\u2013643.","journal-title":"Adv Ther."},{"key":"67_CR4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/157339912800564007","volume":"8","author":"B.K. Irons","year":"2012","unstructured":"Irons BK, Weis JM, Stapleton MR, Edwards KL. An update in incretin-based therapy: a focus on dipeptidyl peptidase-4 inhibitors. Curr Diabetes Rev. 2012;8:169\u2013182.","journal-title":"Curr Diabetes Rev."},{"key":"67_CR5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1463-1326.2006.00691.x","volume":"9","author":"L. Brazg","year":"2007","unstructured":"Brazg L, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and \u03b2-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:186\u2013193.","journal-title":"Diabetes Obes Metab."},{"key":"67_CR6","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1463-1326.2009.01040.x","volume":"11","author":"E. Bosi","year":"2009","unstructured":"Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11:506\u2013515.","journal-title":"Diabetes Obes Metab."},{"key":"67_CR7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12325-011-0028-y","volume":"28","author":"A.H. Barnett","year":"2011","unstructured":"Barnett AH. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv Ther. 2011;28:447\u2013459.","journal-title":"Adv Ther."},{"key":"67_CR8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/CRD.0b013e31823a3afc","volume":"20","author":"R. Aletti","year":"2012","unstructured":"Aletti R, Cheng-Lai A. Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Cardiol Rev. 2012;20:45\u201351.","journal-title":"Cardiol Rev."},{"key":"67_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1517\/14656566.2012.642863","volume":"13","author":"T. Forst","year":"2012","unstructured":"Forst T, Pf\u00fctzner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother. 2012;13:101\u2013110.","journal-title":"Expert Opin Pharmacother."},{"key":"67_CR10","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2165\/11209570-000000000-00000","volume":"72","author":"E.D. Deeks","year":"2012","unstructured":"Deeks ED. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2012;72:1793\u20131824.","journal-title":"Drugs."},{"key":"67_CR11","unstructured":"Boehringer Ingelheim. Jentadueto\u00ae (linagliptin\/metformin hydrochloride) tablets receive approval for the treatment of adults with type 2 diabetes in Europe (media release). Jul 25 2012 (online). Available at: http:\/\/us.boehringer-ingelheim.com\/news_events\/press_releases\/press_release_archive\/2012\/july_25_2012.html . Accessed Jul 25 2012."},{"key":"67_CR12","unstructured":"Boehringer Ingelheim. FDA approves Jentadueto\u2122 (linagliptin\/metformin hydrochloride) tablets for the treatment of adult patients with type 2 diabetes (press release). Jan 30 2012 (online). Available at: http:\/\/us.boehringer-ingelheim.com\/news_events\/press_releases\/press_release_archive\/2012\/january_30_2012.html . Accessed Jan 30 2012."},{"key":"67_CR13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1463-1326.2012.01590.x","volume":"14","author":"T. Haak","year":"2012","unstructured":"Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14:565\u2013574.","journal-title":"Diabetes Obes Metab."},{"key":"67_CR14","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"L.L. Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131\u20132157.","journal-title":"Gastroenterology."},{"key":"67_CR15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-011-0002-3","volume":"2","author":"C. Koliaki","year":"2011","unstructured":"Koliaki C, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2011;2:101\u2013121.","journal-title":"Diabetes Ther."},{"key":"67_CR16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1517\/13543780903463862","volume":"19","author":"C.F. Deacon","year":"2010","unstructured":"Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment oftype 2 diabetes. Expert Opin Investig Drugs. 2010;19:133\u2013140.","journal-title":"Expert Opin Investig Drugs."},{"key":"67_CR17","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270008323753","volume":"48","author":"S. Huttner","year":"2008","unstructured":"Huttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4,in healthy male volunteers. J Clin Pharmacol. 2008; 48:1171\u20131178.","journal-title":"J Clin Pharmacol."},{"key":"67_CR18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1463-1326.2009.01046.x","volume":"11","author":"T. Heise","year":"2009","unstructured":"Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitorin male type 2 diabetes patients. Diabetes Obes Metab. 2009;11:786\u2013794.","journal-title":"Diabetes Obes Metab."},{"key":"67_CR19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","volume":"52","author":"J. Buteau","year":"2003","unstructured":"Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 2003;52:124\u2013132.","journal-title":"Diabetes"},{"key":"67_CR20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1463-1326.2011.01473.x","volume":"14","author":"R.E. Genugten van","year":"2012","unstructured":"van Genugten RE, van Raalte DH, Diamant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes Obes Metab. 2012;14:101\u2013111.","journal-title":"Diabetes Obes Metab."},{"key":"67_CR21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1530\/JOE-11-0479","volume":"214","author":"J. Jelsing","year":"2012","unstructured":"Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves \u03b2-cell mass in non-obese diabetic mice. J Endocrinol. 2012;214:381\u2013387.","journal-title":"J Endocrinol."},{"key":"67_CR22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1463-1326.2012.01586.x","volume":"14","author":"D. Singh-Franco","year":"2012","unstructured":"Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, Harrington C. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2012;14:694\u2013708.","journal-title":"Diabetes Obes Metab."},{"key":"67_CR23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2012.04173.x","volume":"74","author":"U. Graefe-Mody","year":"2012","unstructured":"Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012;74:75\u201385.","journal-title":"Br J Clin Pharmacol."},{"key":"67_CR24","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1517\/17425255.2011.628986","volume":"7","author":"A.J. Scheen","year":"2011","unstructured":"Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opin Drug Metab Toxicol. 2011;7:1561\u20131576.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"67_CR25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.clinthera.2011.06.005","volume":"33","author":"Y. Horie","year":"2011","unstructured":"Horie Y, Kanada S, Watada H, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week, multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 Diabetes Patients. Clin Ther. 2011;33:973\u2013989.","journal-title":"Clin Ther."},{"key":"67_CR26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/jpet.107.135723","volume":"325","author":"L. Thomas","year":"2008","unstructured":"Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl1-(4-methylquinazolin-2ylmethyl) 3,7-dihydro-purine-2,6-dione(BI1356), a novelxanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325:175\u2013182.","journal-title":"J Pharmacol Exp Ther."},{"key":"67_CR27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","volume":"13","author":"M.R. Taskinen","year":"2011","unstructured":"Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65\u201374.","journal-title":"Diabetes Obes Metab."},{"key":"67_CR28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1464-5491.2010.03131.x","volume":"27","author":"T. Forst","year":"2010","unstructured":"Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med. 2010;27:1409\u20131419.","journal-title":"Diabet Med."},{"key":"67_CR29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","volume":"380","author":"B. Gallwitz","year":"2012","unstructured":"Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380:475\u2013483.","journal-title":"Lancet."},{"key":"67_CR30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11892-011-0227-6","volume":"11","author":"P.J. Guillausseau","year":"2011","unstructured":"Guillausseau PJ. Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed. Curr Diab Rep. 2011;11:461\u2013462.","journal-title":"Curr Diab Rep."},{"key":"67_CR31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11892-011-0179-x","volume":"11","author":"B. Ahr\u00e9n","year":"2011","unstructured":"Ahr\u00e9n B. Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes? Curr Diab Rep. 2011;11:83\u201390.","journal-title":"Curr Diab Rep."},{"key":"67_CR32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1185\/03007995.2012.678940","volume":"28","author":"E. Mannucci","year":"2012","unstructured":"Mannucci E, Dicembrini I. Incretin-based therapies and cardiovascular risk. Curr Med Res Opin. 2012;28:715\u2013721.","journal-title":"Curr Med Res Opin."},{"key":"67_CR33","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/dc11-1099","volume":"34","author":"M. Monami","year":"2011","unstructured":"Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34:2474\u20132476.","journal-title":"Diabetes Care."},{"key":"67_CR34","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1517\/14656566.2012.689825","volume":"13","author":"R. Aronson","year":"2012","unstructured":"Aronson R. Combination therapy in type 2 diabetes mellitus: adding linagliptin to a stable regimen of metformin and a sulfonylurea. Expert Opin Pharmacother. 2012;13:1535\u20131539.","journal-title":"Expert Opin Pharmacother."},{"key":"67_CR35","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-5491.2011.03387.x","volume":"28","author":"D.R. Owens","year":"2011","unstructured":"Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011;28:1352\u20131361.","journal-title":"Diabet Med."},{"key":"67_CR36","volume-title":"(linagliptin\/metformin HCI) tablets","author":"Jentadueto\u2122","year":"2012","unstructured":"Jentadueto\u2122 (linagliptin\/metformin HCI) tablets [EMA Summary of Product Characteristics]. Boehringer Ingelheim Inc., Ridgefield, CT, US and Eli Lilly, Indianapolis, IN, US; 2012."},{"key":"67_CR37","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1185\/03007995.2012.714360","volume":"28","author":"S.A. Ross","year":"2012","unstructured":"Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012;28:1465\u20131474.","journal-title":"Curr Med Res Opin."},{"key":"67_CR38","unstructured":"Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu. 2007:13\u201320."},{"key":"67_CR39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","volume":"137","author":"D. Kirpichnikov","year":"2002","unstructured":"Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25\u201333.","journal-title":"Ann Intern Med."},{"key":"67_CR40","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"G. Zhou","year":"2001","unstructured":"Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167\u20131174.","journal-title":"J Clin Invest."},{"key":"67_CR41","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2337\/db07-0381","volume":"57","author":"Y.D. Kim","year":"2008","unstructured":"Kim YD, Park KG, Lee YS, et al. Metformin inhibits hepatic gluconeogenesis through AMP activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2008;57:306\u2013314.","journal-title":"Diabetes."},{"key":"67_CR42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/diacare.24.3.489","volume":"24","author":"E. Mannucci","year":"2001","unstructured":"Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels inobese non-diabetic subjects. Diabetes Care. 2001;24:489\u2013494.","journal-title":"Diabetes Care."},{"key":"67_CR43","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1006\/bbrc.2002.6607","volume":"291","author":"S.A. Hinke","year":"2002","unstructured":"Hinke SA, Kuhn-Wache K, Hoffmann T, et al. Metformin effects on dipeptidyl peptidase IV degradation of glucagon likepeptide-1. Biochem Biophys Res Commun. 2002;291:1302\u20131308.","journal-title":"Biochem Biophys Res Commun."},{"key":"67_CR44","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/11532980-000000000-00000","volume":"49","author":"A.J. Scheen","year":"2010","unstructured":"Scheen AJ. Dipeptidyl peptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010;49:573\u2013588.","journal-title":"Clin Pharmacokinet."},{"key":"67_CR45","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/11630900-000000000-00000","volume":"51","author":"U. Graefe-Mody","year":"2012","unstructured":"Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012;51:411\u2013427.","journal-title":"Clin Pharmacokinet."},{"key":"67_CR46","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1185\/03007990903094361","volume":"25","author":"U. Graefe-Mody","year":"2009","unstructured":"Graefe-Mody U, Padula S, Ringa A, Withopf B, Dugi KA. Evaluation of the potential for steadystate pharmacokinetic and pharmacodynamics interactions between the DPP-inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009;25:1963\u20131972.","journal-title":"Curr Med Res Opin."},{"key":"67_CR47","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2337\/db06-0738","volume":"56","author":"J. Heer de","year":"2007","unstructured":"de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulin tropic effect of glucagon-like peptide 1. Diabetes. 2007;56:438\u2013443.","journal-title":"Diabetes."},{"key":"67_CR48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1463-1326.2012.01565.x","volume":"14","author":"G. Schernthaner","year":"2012","unstructured":"Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:470\u2013478.","journal-title":"Diabetes Obes Metab."},{"key":"67_CR49","unstructured":"Merck Sharp & Dohme Ltd. Januvia\u2122 film-coated tablets: summary of product characteristics [online]. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000722\/WC500039054.pdf . Accessed Dec 8 2009."},{"key":"67_CR50","unstructured":"Bristol-Myers Squibb and AstraZeneca EEIG. Onglyza film-coated tablets: summary of product characteristics [online]. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/001039\/WC500044316.pdf . Accessed Oct 27 2009."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-012-0067-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-012-0067-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-012-0067-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:56:03Z","timestamp":1559447763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-012-0067-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,23]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s12325-012-0067-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,23]]}}}